The U.S. Supreme Court will decide by May 14, 2026, whether to reinstate mifepristone's in-person dispensing requirement nationwide, potentially reversing the FDA's 2023 change allowing telehealth prescriptions and mail distribution. Louisiana's lawsuit challenges this change, with courts finding the state likely has standing. Republican attorneys general from multiple states have filed cases targeting the FDA and out-of-state abortion medication providers, intensifying conflicts with Democratic states' shield laws.

Oklahoma's House approved two measures for an August 25, 2026 special election ballot that would allow lawmakers to modify or end the state's voter-approved Medicaid expansion. One proposal (HB 4440) would move expansion from the constitution to statute; another (HJR 1067) would end expansion if federal funding drops below 90 percent. Similar efforts are underway in South Dakota and Missouri.

Texas and Louisiana pursued legal action against out-of-state abortion providers while enacting laws allowing private citizens to sue those providing abortion medication. Six blue states responded with protective measures allowing facilities rather than individual clinicians on prescription labels. Emergency abortion clarifications passed in Arkansas, Kentucky, Tennessee, and Texas, while Colorado, New York, Washington, Massachusetts, and Connecticut codified federal emergency care protections into state law.